This company has been marked as potentially delisted and may not be actively trading. Epizyme (EPZM) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock EPZM Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period bluebird bio Inc BLUENovember 1, 2023 | morningstar.comMCelgene, Jounce Therapeutics in Early Cancer Immunotherapy Development PactMarch 21, 2023 | thestreet.comEpizyme (NASDAQ:EPZM) Earns Hold Rating from Analysts at StockNews.comOctober 3, 2022 | marketbeat.comAptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal - NasdaqAugust 12, 2022 | nasdaq.comForm SC 14D9/A Epizyme, Inc. Filed by: Epizyme, Inc. - StreetInsider.comAugust 12, 2022 | streetinsider.comEpizyme (Nasdaq:EPZM) HeadlineTrading was temporarily halted for "EPZM" at 07:08 PM with a stated reason of "News pending."...August 12, 2022 | marketbeat.comThe past five years for Epizyme (NASDAQ:EPZM) investors has not been profitableAugust 10, 2022 | finance.yahoo.comEpizyme: Q2 Earnings Insights - BenzingaAugust 9, 2022 | benzinga.comEpizyme Reports Second Quarter 2022 Financial Results and Provides Business Update - Business WireAugust 9, 2022 | businesswire.comEpizyme: Q2 Earnings SnapshotAugust 9, 2022 | apnews.comAIpsen extends tender offer date in Epizyme deal to get US antitrust clearance - Seeking AlphaAugust 5, 2022 | seekingalpha.comIpsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022 - Business WireAugust 5, 2022 | businesswire.comIpsen Delivers Strong H1 2022 Results and Upgrades Its Full-Year Guidance - Yahoo FinanceJuly 28, 2022 | finance.yahoo.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ONEM, EPZM, LION - PR NewswireJuly 26, 2022 | prnewswire.comShareholder Alert - The M&A Class Action Firm Continues Investigating the Merger - FSTX, EPZM, STCN, SIMO - BenzingaJuly 16, 2022 | benzinga.comSHAREHOLDER ALERT: Weiss Law Reminds RFP, ZEN, RDUS, and EPZM Shareholders About Its Ongoing Investigations - PR NewswireJuly 14, 2022 | prnewswire.comEPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM - BenzingaJuly 14, 2022 | benzinga.comForm SC 14D9 Epizyme, Inc. Filed by: Epizyme, Inc. - StreetInsider.comJuly 13, 2022 | streetinsider.comEPIZYME ALERT: Bragar Eagel & Squire, PC Investigates Merger of EPZM and Encourages Investors to Contact the Firm - GuruFocus.comJuly 11, 2022 | gurufocus.comINVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, VIVO, RADA, EPZM - GlobeNewswireJuly 10, 2022 | globenewswire.comMoore Kuehn Encourages EPZM, RDUS, OBCI, and CNVY Investors to Contact Law Firm - PR NewswireJuly 6, 2022 | prnewswire.comEpizyme Acquisition By Ipsen: CVR Value (NASDAQ:EPZM) - Seeking AlphaJuly 6, 2022 | seekingalpha.comINVESTIGATION NOTICE: Halper Sadeh LLP Investigates ZEN, USAK, EPZM - PR NewswireJuly 5, 2022 | prnewswire.comEpizyme : Statement of Changes in Beneficial Ownership (Form 4) - Marketscreener.comJuly 5, 2022 | marketscreener.comMEPIZYME ALERT: Bragar Eagel & Squire, PC Investigates Merger of EPZM and Encourages Investors to Contact the Firm - StreetInsider.comJuly 1, 2022 | streetinsider.comEPIZYME ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of EPZM and Encourages Investors to Contact the FirmJune 30, 2022 | benzinga.comEPIZYME INVESTOR ALERT by the - GuruFocus.comJune 29, 2022 | gurufocus.comIN BRIEF: BioPharma Credit says Epizyme investment to be prepaid | Financial News - London South EastJune 28, 2022 | lse.co.ukShareholder Alert - The M&A Class Action Firm Announces an Investigation of Epizyme, Inc. - EPZM - PR NewswireJune 27, 2022 | prnewswire.comEpizyme, Inc. (NASDAQ:EPZM) Given Average Recommendation of "Hold" by BrokeragesJune 27, 2022 | marketbeat.comShareholder Alert - The M&A Class Action Firm Announces an Investigation of Epizyme, Inc. - EPZMJune 27, 2022 | prnewswire.comEpizyme (NASDAQ:EPZM) Downgraded by Cowen to "Market Perform"June 27, 2022 | marketbeat.comWedbush Downgrades Epizyme to Neutral - Benzinga - BenzingaJune 27, 2022 | benzinga.comThinking about buying stock in Epizyme, Acutus Medical, Agile Therapeutics, Axsome Therapeutics, or Evofem Biosciences? - PR NewswireJune 27, 2022 | prnewswire.comEPZM Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Epizyme, Inc. Is Fair to Shareholders - Business WireJune 27, 2022 | businesswire.comEpizyme Shares Take Flight on Takeover by Ipsen >EPZM - MarketWatchJune 27, 2022 | marketwatch.comEpizyme shares soar 60% on acquisition newsJune 27, 2022 | finance.yahoo.comNorth American Morning Briefing : Hopes for Less Aggressive Fed Spur More Gains for Stocks - Marketscreener.comJune 27, 2022 | marketscreener.comMProsus, miners lift European shares to two-week high - NasdaqJune 27, 2022 | nasdaq.comEuropean Shares Set For Steady Opening As Inflation Worries Ease - NasdaqJune 27, 2022 | nasdaq.comFrance's Ipsen Launches Tender Offer to Purchase US Biopharmaceutical Epizyme - Marketscreener.comJune 27, 2022 | marketscreener.comMIpsen to Acquire Epizyme, Expanding Its Portfolio in Oncology - Business WireJune 27, 2022 | businesswire.comHUTCHMED Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China - GuruFocus.comJune 21, 2022 | gurufocus.comEpizyme's Return On Capital Employed Insights - Benzinga - BenzingaJune 9, 2022 | benzinga.comWhy Is Epizyme (EPZM) Up 51.7% Since Last Earnings Report?June 9, 2022 | finance.yahoo.comHC Wainwright & Co. Maintains Buy on Epizyme, Lowers Price Target to $6 - Benzinga - BenzingaJune 3, 2022 | benzinga.comEpizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting - Business WireJune 2, 2022 | businesswire.comEpizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting - StreetInsider.comJune 2, 2022 | streetinsider.comEpizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting - Yahoo FinanceJune 2, 2022 | finance.yahoo.comEpizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual MeetingJune 2, 2022 | finance.yahoo.com Get Epizyme News Delivered to You Automatically Sign up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter. Email Address EPZM Media Mentions By Week EPZM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EPZM News Sentiment▼0.220.88▲Average Medical News Sentiment EPZM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EPZM Articles This Week▼00▲EPZM Articles Average Week Get Epizyme News Delivered to You Automatically Sign up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ZYME News CMRX News CDMO News RVNC News CKPT News MBX News AVTE News TSVT News SLRN News CYBN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EPZM) was last updated on 7/1/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Epizyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Epizyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
